Article
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Sept 2018
Treon Steven P, Gustine Joshua, Meid Kirsten, Yang Guang, Xu Lian, Liu Xia, Demos Maria, Kofides Amanda, Tsakmaklis Nicholas, Chen Jiaji G, Munshi Manit, Chan Gloria, Dubeau Toni, Raje Noopur, Yee Andrew, O'Donnell Elizabeth, Hunter Zachary R, Castillo Jorge J
Abstract excerpt
Purpose Ibrutinib is active in previously treated Waldenström macroglobulinemia (WM). MYD88 mutations ( MYD88MUT) and CXCR4 mutations ( CXCR4MUT) affect ibrutinib response. We report on a prospective study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect of CXCR4MUT status on outcome. Patients and Methods Symptomatic, treatment-naïve patients with WM were eligible. Ibrutinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.